Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat | Zendy

Elise J. Smolders | Zendy; E. P. H. Colbers | Zendy; Clara T. M. M. de Kanter | Zendy; Kirsten VelthovenGraafland | Zendy; Joost P.H. Drenth | Zendy; David M. Burger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat

Author(s) -

Elise J. Smolders,

E. P. H. Colbers,

Clara T. M. M. de Kanter,

Kirsten VelthovenGraafland,

Joost P.H. Drenth,

David M. Burger

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw429

Subject(s) - atazanavir , daclatasvir , cobicistat , cmax , ritonavir , medicine , pharmacokinetics , pharmacology , cmin , virology , viral load , human immunodeficiency virus (hiv) , hepatitis c virus , virus , ribavirin , antiretroviral therapy

Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir. When combined with the CYP3A4 substrate daclatasvir, the daclatasvir dosage should be reduced from 60 to 30 mg once daily. Recently, cobicistat was licensed as a CYP3A booster and used with atazanavir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research